home / stock / lxrx / lxrx news

LXRX News and Press, Lexicon Pharmaceuticals Inc. From 03/25/24

Stock Information
Company Name: Lexicon Pharmaceuticals Inc.
Stock Symbol: LXRX
Market: NASDAQ
Website: lexpharma.com
Menu
LXRX LXRX Quote LXRX Short LXRX News LXRX Articles LXRX Message Board
Get LXRX Alerts

News, Short Squeeze, Breakout and More Instantly...
LXRX - WPRT, FIVN and FATE are among after hour movers

2024-03-25 17:15:09 ET Gainers: Stoke Therapeutics ( STOK ) +87% . AnaptysBio ( ANAB ) +8% . Amneal Pharmaceuticals ( AMRX ) +6% . Omega Therapeutics ( OMGA ) +5% . MoneyHero  ( MNY ) +5% . Losers: Ocular Therapeutix...
LXRX - Lexicon Pharmaceuticals files to sell 57.66M shares for holders

2024-03-25 16:35:19 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalizat...

LXRX - Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins (SGLT2 and SGLT1), will be delivered during the American Colle...

LXRX - Lexicon stock slides 8% after rallying 30% in prior session

2024-03-12 11:38:13 ET Read the full article on Seeking Alpha For further details see: Lexicon stock slides 8% after rallying 30% in prior session
LXRX - New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial demonstrated that treatment with sotagliflozin resulted in improved glycemic control in patients...

LXRX - Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

2024-03-12 03:57:11 ET Summary Lexicon Pharmaceuticals is actively working to create shareholder value by pursuing new indications for the lead drug sotagliflozin. The company reported $0.7 million in Inpefa sales for Q4 2023, below expectations, but these are still early days for...

LXRX - Lexicon Pharmaceuticals GAAP EPS of -$0.20 in-line, revenue of $0.7M misses by $1.24M

2024-03-11 16:51:09 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value Lexicon Pharmaceuticals: Navigatin...
LXRX - Lexicon stock rallies 18% amid FDA update, $250M private placement

2024-03-11 12:15:43 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value Lexicon Pharmaceuticals: Navigatin...

LXRX - Lexicon Pharmaceuticals GAAP EPS of -$0.20 beats by $0.02, revenue of $0.7M misses by $0.54M

2024-03-11 12:13:19 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value Lexicon Pharmaceuticals: Navigatin...

LXRX - Lexicon announces oversubscribed $250M private placement of equity securities

2024-03-11 11:52:44 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value Lexicon Pharmaceuticals: Navigatin...
Previous 10 Next 10